Deletion of a non-imprinted 500Kb genomic region at chromosome 15q11.2, between breakpoints 1 and 2 of the Prader-Willi/Angelman locus (BP1-BP2 deletion) has been associated in previous studies with phenotypes including developmental delay, autism, schizophrenia and congenital cardiovascular malformations (CVM). The deletion has a low baseline population prevalence and large-scale data regarding the magnitude of these associations and any milder effects on cognition phenotypes, in populations not selected for disease, are limited.
Introduction
Copy number variants (CNVs) are a form of genomic structural variation consisting of deletions or duplications of genetic material. These variations may encompass the coding regions of multiple genes. CNVs are known to be common, possibly accounting for as much as 13% of the human genome 1 . Studies have concluded that CNVs which occur commonly in the population are unlikely to contribute significantly to human disease 2 , while in some cases the presence of CNVs may confer a functional advantage 3 . However, many genes are sensitive to copy number and alterations can lead to dosage imbalance 4 . Consequently many rare CNVs have been identified that are associated with a variety of diseases including schizophrenia 5, 6 , autism 7 , developmental disorders 8, 9 and congenital cardiovascular malformations (CVM) 10 .
15q11.2 BP1-BP2 deletions occur between breakpoints 1 and 2 (BP1-BP2) on the long arm of chromosome 15 and encompass 4 genes (NIPA1, NIPA2, CYFIP1 and TUBGCP5) within a 500kb region ( Figure 1 ). The BP1-BP2 region is immediately adjacent to the imprinted regions of chromosome 15 that cause Prader-Willi and Angelman syndromes, but the four genes within the BP1-BP2 region are not themselves imprinted. Individuals with this microdeletion have increased risk of a range of neuropsychiatric phenotypes including developmental and speech delays [11] [12] [13] , autism spectrum disorders 14 , attention deficit disorders (ADD) 15 and schizophrenia 16 . As with other CNVs causing complex phenotypes (for example 22q11.2 deletion, 1q21.1 duplication), penetrance and expressivity shows wide variation. Penetrance of any phenotype with 15q11 BP1-BP2 deletion has been estimated at ~10-12% 11, 17 which is relatively low compared to other CNVs commonly associated with genetic disorders. Taken together, previous studies estimate the prevalence of BP1-BP2 deletion as approximately 0.25% in apparently healthy controls 14 , with individual studies ranging from 0.19% to 0.47% in cohorts of up to 101,655 individuals 11, [16] [17] [18] [19] [20] .
Genomic deletions are known to be a significant cause of congenital malformations, among which congenital cardiovascular malformations (CVM) have the highest population prevalence [21] [22] [23] [24] [25] . We previously identified twelve heterozygous 15q11.2 BP1-BP2 deletions in a cohort of 2,256 patients with a range of non-syndromic CVM phenotypes, and only 1 in 1,538 controls, inferring association of the deletion with CVM risk (OR = 8.2; p = 0.02) 26 . Other studies have found the deletion overrepresented in patients presenting with intellectual disability who also have CVM 11, 15, 27, 28 compared to controls, but data is sparse regarding the association of CVM with this deletion in large populations unselected for disease.
The UK Biobank (UKB), comprising ~500,000 individuals with genotype data, hospital admission records, baseline cognitive function testing, and a variety of other collected information, provides a large-scale resource for investigating complex genotype-phenotype associations. Here we determine the prevalence of BP1-BP2 deletions within the UK Biobank cohort and explore its association with neurodevelopmental diagnoses, cognitive function and CVM.
Methods

CNV calling
B-allele frequency (BAF) and log2ratio (L2R) transformed intensity value files, generated and made available by UKB using the Applied Biosystems UK BiLEVE Axiom and UK Biobank Axiom arrays (n=488,366), were used to generate CNV calls using the PennCNV software 29 . Samples were grouped for CNV calling in batches of ethnically similar samples based on the ethnicity categories defined by UKB (White, Asian or Asian British, Black or Black British, Chinese, Mixed, Other/Unknown).
Ethnically 'white' samples were further batched for CNV calling into batches of 10,000 samples due to the large number of individuals in this category. PennCNV was run using GCmodel adjustment 30 and, following genome-wide CNV calling, samples with waviness factor (WF) less than -0.03 or greater than 0.03 were excluded (n=301). Samples containing an excess of CNVs (>40) (n=1401) were also removed at this stage. This threshold intentionally retained samples with a relatively high number of CNVs as global CNV burden has previously been found to contribute to the risk of sporadic CVM 26 . 15q11.2 deletions were identified where a heterozygous deletion spanned at least 95% of the 4 genes between involved (NIPA1, NIPA2, CYFIP1 and TUBGCP5) between the outer-most array probes covering this region (chr15:22,819,338-23,093,090; GRCh37).
Neuropsychiatric classification
The hospital episode statistics (HES) available in the UKB contains information on hospital admissions for the cohort. It includes primary and secondary diagnoses in the form of ICD9 and ICD10 codes, as well as details of operations and procedures through OPCS-4 codes. Classification of neuropsychiatric conditions was determined using ICD10 codes relating to a subset of 'mental and behavioural disorders' (Table   S1A ) including schizophrenia, bipolar disorders, autism, mental retardation and various neurodevelopmental disorders to classify case individuals. Individuals with any other code in the mental and behavioural classification (Table S1B) were excluded from the control group. This resulted in 3504 case and 483,330 control individuals for neuropsychiatric disorders with CNV calls passing QC thresholds that were then assessed for the presence of BP1-BP2 deletion.
Cognitive function
UKB participants completed a series of cognitive function tests. We correlated performance in these tests with the presence and absence of the BP1-BP2 deletion.
Cognitive function in carriers of a range of neurodevelopmental CNVs has been previously assessed in the first release of UKB (~150,000 individuals) 31 . Here, as BP1-BP2 deletions have been shown to associate with developmental delay, autism and behavioural issues previously, and our focus was to investigate the impact of the deletion in people without diagnosed neuropsychiatric conditions, we removed samples from the whole cohort with ICD10 codes present in the HES with specific diagnoses relating to mental and behavioural disorders previously associated with 15q11.2 deletion (Table S1A ). In total there were 3,691 samples that matched at least one of these ICD10 codes and were subsequently removed from the cognitive function analysis.
We used results from cognitive function tests where the number of participants was at least 10% of the cohort and the test returned numerical data. Tests for 'reaction time', 'numeric memory', 'fluid intelligence' and 'pairs matching' met these criteria with varying amounts of missing data (Table S2 ). The test for reaction time is based on the card game 'snap'. A button is pushed by the participant as rapidly as possible when two cards shown on a screen are matching. We used the reported mean time to correctly identify matches over 12 rounds. In the numeric memory test a participant is shown increasingly long numbers (in terms of digits) and asked to recall them after a short period. Here we took the maximum number of digits correctly remembered. In the test for fluid intelligence a participant has 2 minutes to complete as many questions as possible that require logic and reasoning ability, independent of acquired knowledge. The score is the number of correctly answered questions. Finally, the pairs matching test asks participants to memorise the position of matching pairs of cards that are then turned over. We have used the number of incorrect matches in a round as an indication of success in this test.
CVM classification
Using the classification schema shown in Figure 2 , ICD9, ICD10, OPCS-4 and selfreported illness and operation codes were used to classify 2792 UK Biobank samples as having CVM and 472,378 samples as controls in a similar protocol to Saha et al. 32 .
To ensure that CVM-classified individuals were non-syndromic we excluded a number of syndromes with possible links to cardiovascular defects from the cohort (codes listed in Table S3A ). Following this, the initial inclusion criterion for case status was HES evidence of ICD9 or ICD10 codes for 'congenital malformations of the circulatory system' (Table S3B ). Within these, the ICD10 code Q211 can be used for both 'atrial septal defect' (ASD) and 'patent foramen ovale' (PFO). Since PFO is a normal variant found in up to 25% of the population, we carried out further classification to identify and remove PFOs from the case group. Any sample with a PFO-specific operation code (K165) in addition to a Q211 code was classified as PFO. As PFO is often diagnosed during a stroke workup 33 we also used any diagnosis of stroke without atrial fibrillation prior to Q211 diagnosis as an indicator of PFO rather than ASD. This is because ASD is a common cause of atrial fibrillation, which is a risk factor for stroke, whereas PFO (prior to device closure) is not associated with a significantly increased predisposition to atrial fibrillation (all codes in Table S3C ). OPCS-4 codes for operations commonly associated with congenital heart defects were also used to classify CVM (Table S3D ).
In addition to codes covering 'congenital malformation of the circulatory system', we used additional codes to identify, amongst others, certain defects of congenital origin presenting in later life (Table S3E ). Chief among these were codes indicating congenital bicuspid aortic valve (BAV), a condition affecting ~1% of males and ~0.33% of females. We included codes for aortic stenosis and aortic insufficiency as well as associated operational codes. We also used self-reported operation and illness codes (full list Table S3F ) indicating 'aortic valve replacement', 'aortic stenosis' and 'aortic regurgitation' as evidence of BAV. An age threshold of diagnosis at younger than 65 years was applied to distinguish individuals with aortic valve disease due to BAV from those with age-related degeneration of a trileaflet aortic valve 34 , as previously implemented by Helle et al. 35 . Additional filters were applied to exclude any participants with a diagnosis of other conditions (such as bacterial endocarditis) that might cause non-congenital valve defects. The codes and descriptions of these exclusion diagnoses are listed in Table S3G . Individuals with no evidence of CVM phenotypes were classified as controls. Other diagnosed conditions that could potentially have a confounding influence on the classification were excluded from the control set (e.g. PFO-categorised samples, acquired heart defects, samples with evidence of aortic valve disease above the specified age threshold). The full list of excluded codes can be found in Table S3H . Finally, deceased UKB participants with or without CVM classifying ICD codes, obtained by UKB from the UK Office for National Statistics, were classified as CVM cases or controls accordingly.
Statistical analysis
The frequency of BP1-BP2 deletion in cases of CVM and controls as well as neuropsychiatric disorder cases and controls was compared using chi-squared tests.
Associations between the deletion and quantitative measures of cognitive function
were assessed using different statistical models dependent upon the distribution of the data, and adjusting for age and sex. Linear regression was used for reaction time 
Results
The prevalence of BP1-BP2 deletion in neuropsychiatric disorder cases
We first assessed the prevalence of BP1-BP2 deletion in individuals diagnosed with a neuropsychiatric disorder. 3504 individuals were found to have a relevant diagnosis in the HES data (see Methods). Of these, 24 carried the deletion, a prevalence of 0.68%, which was different from the control group (OR=1.84 [95% CI 1.23 -2.75]; p=0.0043) ( Table 1 ). The specific diagnoses of these 24 individuals can be found in Table S4A .
BP1-BP2 deletions and cognitive function
After removing participants with relevant neuropsychiatric disorders (See Methods), 483,330 samples remained. Of these, 1808 carried the BP1-BP2 deletion. Figure 3 shows the differences between the two groups in terms of the scores in 4 different cognitive function tests. Table 2 summarises the results of these tests and indicates differences in performance between individuals with and without BP1-BP2 deletion, after adjustment for participant age and sex.
BP1-BP2 deletions and academic achievement
Carriers of the BP1-BP2 deletion were compared to non-carriers in terms of the highest academic qualifications that they had achieved. Table 3 
The prevalence of BP1-BP2 deletion in non-syndromic cardiovascular malformation
In total, 2792 participants with genetic data available were identified as having nonsyndromic CVM and 472,378 were classified as controls (See Methods). Table 4 shows a list of the most common CVM diagnoses and associated sample numbers in UKB based upon compiling relevant ICD9, ICD10, OPCS-4 and self-reported codes.
A full list of these codes along with diagnoses and associated number of individuals can be found in Table S5 . Of the participants with CVM, the most common diagnoses relate to the presence of bicuspid aortic valve (BAV). We inferred bicuspid aortic valve from any aortic valve diagnosis (aortic stenosis, regurgitation, unspecified problem or replacement) after childhood but before age 65 in the absence of a diagnosis of infective endocarditis (see Methods).
In total, 1832 BP1-BP2 deletions were identified in UKB participants with genotyping data available. The CVM and control groups accounted for a total of 1787 of the samples with BP1-BP2 deletion, with 45 deletions present in participants who were excluded according to the criteria above. Of the 2792 non-syndromic CVM samples, 18 carried the BP1-BP2 deletion resulting in an estimated prevalence of 0.64% (Table 5 ). The specific phenotypes and classifying codes of these cases are summarised in Table S1B . Of 472,378 control samples, 1769 carried the BP1-BP2 deletion resulting in a prevalence of 0.38% (OR=1.73 [95% CI 1.08 -2.75]; p=0.02995). In keeping with previous observations, no participant was homozygous for the BP1-BP2 deletion.
Two of the 18 CVM-case samples carrying the BP1-BP2 deletion were also found to have neuropsychiatric-related diagnoses. Those individuals had cardiovascular diagnoses of atrial septal defect and aortic valve disease/replacement; and neuropsychiatric diagnoses of bipolar disorder and scholastic developmental disorders respectively.
BP1-BP2 deletions and fecundity
Fecundity was assessed in those individuals with and without the BP1-BP2 deletion.
Self-reported number of children fathered (for males) and number of live births (for females) in each cohort is shown in Figure 4 . A difference was identified in males between those individuals carrying the BP1-BP2 deletion and those without (mean number of children fathered = 1.66 and 1.8 respectively; p=0.00175). This difference was not evident in females (mean number of live births = 1.88 and 1.82 in BP1-BP2 deletion carriers and non-carriers respectively; p=0.18). A test for interaction confirmed the differences between the male and female subgroups (p-interaction=5.46E-04).
Discussion
The 15q11.2 (BP1-BP2) deletion (sometimes referred to as the Burnside-Butler syndrome susceptibility locus) has previously been associated with phenotypes including developmental delay, autism, schizophrenia and CVM; the great majority of the evidence regarding the deletion thus far originates from cohorts specifically selected for one or other of those phenotypes. We estimated the prevalence of the deletion and its associations in the UK Biobank cohort. We confirmed the association of the deletion with neuropsychiatric disorders (OR=1.84 [95% CI 1.23 -2.75]; p=0.0043); and with CVM (OR=1.73 [95% CI 1.08 -2.75]; p=0.03).
Estimates of the prevalence of BP1-BP2 deletion have varied widely in the literature.
The largest previous study, by Stefansson et al. 20 showed a general population prevalence of 0.23% (95% CI 0.21-0.26), in 101,655 Icelandic subjects of whom 241 carried the BP1-BP2 deletion. Given differences in recruitment strategies, genotyping methodologies and populations, direct comparison between this figure and our estimate of 0.37% (95% CI 0.36-0.39) is not straightforward; however, they are broadly consistent with each other. The previous study by Stefansson had also shown nominally reduced fecundity among 172 carriers of the BP1-BP2 deletion who were over 45 years of age. In UKB we observed reduced fecundity in males carrying this deletion (p=0.00175) (Figure 4 ), supporting these findings in a much larger cohort.
Stefansson et al. concluded that the neuropsychiatric manifestations of the BP1-BP2 deletion in carriers without schizophrenia were most evident on dyslexia and dyscalculia 20, 36 . The present study had a less extensive range of cognitive function tests, but with larger numbers of deletion carriers we observed a more general effect on cognitive function among carriers who had not been diagnosed with a neuropsychiatric disorder. Additionally, we showed sizeable associations between the deletion and lower educational attainment. Deletion carriers were considerably less likely to obtain Advanced level qualifications, which in the UK system are required for University entrance; and whereas about one-third of UKB participants without BP1-BP2 deletion had a University or College degree, less than one-quarter of deletion carriers had this as their highest educational qualification.
We confirmed the association of BP1-BP2 deletion with CVM, which has been observed in some but not all previous studies. The first study linking BP1-BP2 deletions with non-syndromic CVM showed an odds ratio of 8.2 (P=0.02); the risk associated with the deletion was much smaller in this study. Of note, there are major differences in the range of phenotypes in both studies, with a much milder range of CVM phenotypes predominating in UKB. Indeed, CVM phenotypes occurred at lower rates than anticipated in UKB, which is known to exhibit a "healthy cohort effect" in multiple domains. Most UKB participants with CVMs had bicuspid aortic valve, which was excluded from the hypothesis-generating study; moreover, the prevalence of BAV diagnosed from the HES data in UKB was significantly lower than anticipated, indicating misclassification bias could affect the risk estimate.
Larger cohorts of homogeneous phenotypes will be required in order to establish the role of the deletion in specific CVM phenotypes. In future studies, availability of electronic health records from the General Practitioners of UKB participants, may mitigate any misclassification bias in respect of CVMs.
The clinical and genetic aspects of BP1-BP2 deletion have been recently reviewed 37 .
Four genes, TUBGCP5, CYFIP1, NIPA1, and NIPA2, are located in the deleted region. The deletion is recognised as a susceptibility locus for presentations with intellectual impairment, autism, schizophrenia, and epilepsy with a low penetrance estimated at around 10%. The effects of hemizygosity at each individual gene in the region have not been systematically described in mouse models, nor has any mouse model of the entire deletion been reported as yet. Therefore, the mechanisms whereby the deletion causes its associated phenotypes, and the interaction between hemizygosity for the region and other genetic and environmental factors to result in the wide variety of phenotypes described, remain to be elucidated.
In conclusion, we have explored the phenotypic associations of the BP1-BP2 deletion in the largest cohort studied to date. We demonstrate an association with the less severe CVM phenotypes prevalent in the UKB cohort, albeit of small magnitude, as well as confirming the association with neuropsychiatric disorders. We have found broad general effects on cognitive function in carriers of the deletion and evidence of disparity in academic qualifications that have been achieved by carriers compared to non-carriers. Given reduced cognitive function in non-diagnosed carriers, these findings highlight important clinical and societal implications of the BP1-BP2 deletion, and are of potential use in deciding appropriate criteria for clinical genetic testing. Table 5 . The number and prevalence of BP1-BP2 deletions in non-syndromic CVM cases compared to controls in UK Biobank. Table S3 . 
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